Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT03113578 · ClinicalTrials.gov registry record
Evaluation of the DiLumen Device During Colonoscopy
A clinical trial, sponsored by Lumendi.
- Completed
- Registry status
- 30
- Enrollment target
NCT03113578: Completed study, sponsored by Lumendi.
NCT03113578 is a clinical trial that has completed, run by Lumendi. The registered enrollment target is 30 participants. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT03113578 has completed, sponsored by Lumendi.
- COMPLETED
- Registry status
- 30 participants
- Enrollment target
Study Summary
This is an observational registry study collecting data on the clinical performance of the study device (DiLumen™ ) for its intended use. The primary objective is to evaluate functional outcomes of the DiLumen device in humans. The secondary objective is to evaluate safety characteristics of the DiLumen device.
Primary Outcome
Ability to reach cecum with the study device and scope \[Y or N\]
Interventions
- DEVICE DiLumen
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 30 participants |
| Start Date | 2017-04-26 |
| Est. Completion | 2017-09-27 |
What the finished NCT03113578 record still lists
NCT03113578 is an observational study that tracks outcomes without assigning an intervention. The registry caps enrollment at 30 participants, a relatively small participant target.
The record links to 0 conditions, and to 1 intervention - of which DiLumen is the first listed.
NCT03113578 does not publish any study locations in the registry export this page uses.
Frequently Asked Questions
What is clinical trial NCT03113578 about?
NCT03113578 is a clinical study titled "Evaluation of the DiLumen Device During Colonoscopy". This is an observational registry study collecting data on the clinical performance of the study device (DiLumen™ ) for its intended use. The primary objective is to evaluate functional outcomes of the DiLumen device in humans. The secondary objective is to evaluate safety characteristics of the DiL...
What is the current status of trial NCT03113578?
This trial is currently completed. The enrollment target is 30 participants. The study started on 2017-04-26. Estimated completion is 2017-09-27.
What interventions are being tested in trial NCT03113578?
The interventions under investigation include: DiLumen (DEVICE).
Who is sponsoring clinical trial NCT03113578?
This trial is sponsored by Lumendi, which has 2 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT00977977 · 30 participants · Phase 2
Rituximab Plus Cyclosporine in Idiopathic Membranous Nephropathy
- NCT01459107 · 30 participants · Phase 2
Human Upper Extremity Allotransplantation
- NCT01666080 · 30 participants · NA
Second or Greater Allogeneic Hematopoietic Stem Cell Transplant Using Reduced Intensity Conditioning (RIC)
- NCT01720836 · 30 participants · Phase 1
Study of the Immune Response of MUC1 (Mucin1) Peptide Vaccine for Non-small Cell Lung Cancer
Similar registry start date
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia
- NCT07125183 · started 2026-12 · Phase 2
Study on Efficacy and Tolerability of Weekly Doxorubicin in Elderly Patients With Advanced or Metastatic Leiomyosarcoma
- NCT07292298 · started 2026-11 · Phase 2
Phase 2 Single-Arm Rectal Cancer Brachytherapy for Patients With Low-Lying Residual Adenocarcinoma After Total Neoadjuvant Therapy to Improve Organ Preservation Rates
- NCT04263285 · started 2026-10 · NA
Treatment of Depression Post-SCI